Abstract
Dementia is becoming a worldwide phenomenon. Alzheimer’s disease represents the first cause of cognitive impairment followed by vascular dementia and fronto-temporal dementia. However, in addition to these well-studied dementia causes there is a wide number of conditions that can cause dementia as infections, toxic-metabolic conditions, inflammatory-autoimmune disorders, or metabolic inborn errors. These uncommon dementia causes, due to the heterogeneous clinical presentation, lack of diagnostic criteria, and rare frequency are often misdiagnosed. Their prevalence has been only partially estimated among young patients (age at onset <65 years), and their management is based only on some expert suggestions. However, a correct diagnosis is of a great importance, since some of them are treatable and reversible dementias.
This chapter presents a comprehensive summary of etiologies, clinical presentation, typical features, diagnostic strategies, and treatments of known uncommon dementias.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Rossor MN, Fox NC, Mummery CJ, et al. The diagnosis of young-onset dementia. Lancet Neurol. 2010;9:793–806.
Harvey RJ, Skelton-Robinson M, Rossor MN, et al. The prevalence and causes of dementia in people under the age of 65 years. J Neurol Neurosurg Psychiatry. 2003;74:1206–9.
Fujihara S, Brucki SM, Rocha MS, et al. Prevalence of presenile dementia in a tertiary outpatient clinic. Arq Neuropsiquiatr. 2004;62(3):592–5.
Panegyres PK, French K. Course and causes of suspected dementia in young adults: a longitudinal study. Am J Alzheimers Dis Other Demen. 2007;22(1):48–56.
Shinagawa S, Ikeda M, Toyota Y, et al. Frequency and clinical characteristics of early-onset dementia in consecutive patients in a memory clinic. Dement Geriatr Cogn Disord. 2007;24(1):42–7.
Kelley BJ, Boeve BF, Josephs KA. Young-onset dementia: demographic and etiologic characteristics of 235 patients. Arch Neurol. 2008;65(11):1502–8.
Sampson EL, Warren JD, Rossor MN. Youn onset dementia. Postgrad Med J. 2004;80:125–39.
Kuruppu DK, Matthews BR. Young-Onset Dementia. Semin Neurol. 2013;33:365–85.
Roos RA. Huntington’s disease: a clinical review. Orphanet J Rare Dis. 2010;5:40–8.
Wyant KJ, Ridder AJ, Dayalu P. Huntington’s disease—update on treatments. Curr Neurol Neurosci Rep. 2017;17:33.
Sorbi S, Hort J, Erkinjuntti T, et al. EFNS-ENS guidelines on the diagnosis and management of disorders associated with dementia. Eur J Neurol. 2012;19:1159–79.
Gallina P, Paganini M, Lombardini L, et al. Progress in restorative neurosurgery: human fetal striatal transplantation in Huntington’s disease. Review. J Neurosurg Sci. 2011;55(4):371–81.
Paganini M, Biggeri A, Romoli AM et al. Fetal striatal grafting slows motor and cognitive decline of Huntington’s disease. J Neurol Neurosurg Psychiatry. 2014.
De Antonio M, Dogan C, Hamroun D, et al. Unravelling the myotonic dystrophy type 1 clinical spectrum: a systematic registry-based study with implications for disease classification. Rev Neurol. 2016;172:572–80.
Gourdon G, Meola G. Myotonic dystrophies: state of the art of new therapeutic developments for the CNS. Front Cell Neurosci. 2017;11:101. https://doi.org/10.3389/fncel.2017.00101.
Rossia M, Perez-Lloretb S, Doldand L, et al. Autosomal dominant cerebellar ataxias: a systematic review of clinical features. Eur J Neurol. 2014;21:607–15.
Murphy S, Gorman G, Beetz C, et al. Dementia in SPG4 hereditary spastic paraplegia: clinical, genetic, and neuropathologic evidence. Neurology. 2009;73(5):378–84.
Bourgeois J, Coffey S, Rivera SM, et al. Fragile X premutation disorders – expanding the psychiatric perspective. J Clin Psychiatry. 2009;70(6):852–62.
Hagerman RJ, Hall DA, Coffey S, et al. Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problems. Clin Interv Aging. 2008;3(2):251–62.
Mila M, Alvarez-Mora MI, Madrigal I, Rodriguez-Revenga L. Fragile X syndrome: an overview and update of the FMR1 gene. Clin Genet 2017. doi: https://doi.org/10.1111/cge.13075.
Parikh S, Bernard G, Leventer RJ, et al. A clinical approach to the diagnosis of patients with leukodystrophies and genetic leukoencephalopathies. Mol Genet Metab. 2015;114:501–15.
Lynch DS, Zhang WJ, Lakshmanan R, et al. Analysis of mutations in AARS2 in a series of CSF1R-negative patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. JAMA Neurol. 2016;73(12):1433–9.
Vanderver A. Genetic leukoencephalopathies in adults. Continuum (Minneap Minn). 2016;22(3):916–42.
Nannucci S, Donnini I, Pantoni L. Inherited leukoencephalopathies with clinical onset in middle and old age. J Neurol Sci. 2014;347(1–2):1–13.
Köhler W. Leukodystrophies with late disease onset: an update. Curr Opin Neurol. 2010;23(3):234–41.
Luda E, Barisone MG. Adult-onset adrenoleukodystrophy: a clinical and neuropsychological study. Neurol Sci. 2001;22:21–5.
Turk BR, Moser AB, Fatemi A. Therapeutic strategies in adrenoleukodystrophy. Wien Med Wochenschr. 2017;167:219–22.
Debs R, Froissart R, Aubourg P, et al. Krabbe disease in adults: phenotypic and genotypic update from a series of 11 cases and a review. J Inherit Metab Dis. 2013;36:859–68.
Lim SM, Choi B-O, Oh S-i, et al. Patient fibroblasts-derived induced neurons demonstrate autonomous neuronal defects in adult-onset Krabbe disease. Oncotarget. 2016;7(46):74496–509.
Gieselmann V, Krägeloh-Mann I. Metachromatic leukodystrophy – an update. Neuropediatrics. 2010;41:1–6.
Penati R, Fumagalli F, Calbi V, et al. Gene therapy for lysosomal storage disorders: recent advances for metachromatic leukodystrophy and mucopolysaccharidosis I. J Inherit Metab Dis. https://doi.org/10.1007/s10545-017-0052-4.
Rademakers R, Baker M, Nicholson AM, et al. Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. Nat Genet. 2012;44:200–5.
Konnoa K, Yoshidac T, Mizuno T, et al. Clinical and genetic characterization of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia associated with CSF1R mutation. Eur J Neurol. 2017;24:37–45.
Eichler FS, Li J, Guo Y, et al. CSF1R mosaicism in a family with hereditary diffuse leukoencephalopathy with spheroids. Brain. 2016;139:1666–72.
Dallabona C, Diodato D, Kevelam SH, Haack TB, Wong LJ, Salomons GS, et al. Novel (ovario) leukodystrophy related to AARS2 mutations. Neurology. 2014;82:2063–71.
Lakshmanan R, Adams ME, Lynch DS, et al. Redefining the phenotype of ALSP and AARS2 mutation-related leukodystrophy. Neurol Genet. 2017;3(2):e135.
Fraidakis MJ. Psychiatric manifestations in cerebrotendinous xanthomatosis. Transl Psychiatry. 2013:1–11.
Appadurai V, DeBarber A, Chiang P-W, et al. Apparent underdiagnosis of Cerebrotendinous Xanthomatosis revealed by analysis of ~60,000 human exomes. Mol Genet Metab. 2015;116(4):298–304.
Pareyson D, Fancellu R, Mariotti C, et al. Adult-onset Alexander disease: a series of eleven unrelated cases with review of the literature. Brain. 2008;131:2321–31.
Mochel F, Schiffmann R, Steenweg ME, et al. Adult polyglucosan body disease: natural history and key magnetic resonance imaging findings. Ann Neurol. 2012;72(3):433–41.
Carra-Dalliere C, Horzinski L, Ayrignac X, et al. Natural history of adult-onset eIF2B-related disorders: a multicentric survey of 24 cases. Rev Neurol (Paris). 2011;167(11):802–11.
Tan RY, Markus HS. Monogenic causes of stroke: now and the future. J Neurol. 2015;262:2601–16.
Narayan SK, Gorman G, Kalaria RN, et al. The minimum prevalence of CADASIL in northeast England. Neurology. 2012;78(13):1025–7.
Søndergaarda CB, Nielsenb JE, Hansena CK, Christensena H. Hereditary cerebral small vessel disease and stroke. Clin Neurol Neurosurg. 2017;155:45–57.
Kaufman KR, Zuber N, Rueda-Lara MA, et al. MELAS with recurrent complex partial seizures, non convulsive status epilepticus, psychosis, and behavioral disturbances: case analysis with literature review. Epilepsy Behav. 2010;18(4):494–7.
McFarland R, Taylor RT, Turnbull DM. A neurological perspective on mitochondrial disease. Lancet Neurol. 2010;9:829–40.
Sigmundsdottir L, Tchan MC, Knopman AA, et al. Cognitive and psychological functioning in Fabry disease. Arch Clin Neuropsychol. 2014;29(7):642–50.
El Dib R, Gomaa H, Ortiz A, et al. Enzyme replacement therapy for AndersonFabry disease: a complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies. PLoS One. 2017;12(3):e0173358. https://doi.org/10.1371/journal.pone.0173358.
Stirnemann J, Belmatoug N, Camou F, et al. A review of Gaucher disease pathophysiology, clinical presentation and treatments. Int J Mol Sci. 2017;18(2):pii: E441. https://doi.org/10.3390/ijms18020441.
O’Regan G, deSouza RM, Balestrino R, Schapira AH. Glucocerebrosidase mutations in Parkinson disease. J Parkinsons Dis. 2017. https://doi.org/10.3233/JPD-171092.
Vanier MT. Niemann-pick disease type C. Orphanet J Rare Dis. 2010;5:16.
Berkovic SF, Staropoli JF, Carpenter S, et al. Diagnosis and misdiagnosis of adult neuronal ceroid lipofuscinosis (Kufs disease). Neurology. 2016;87(6):579–84.
Geraets RD, Koh SY, Hastings ML, et al. Moving towards effective therapeutic strategies for neuronal Ceroid Lipofuscinosis. Orphanet J Rare Dis. 2016;11:40.
Neudorfer O, Pastores GM, Zeng BJ, et al. Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients. Genet Med. 2005;7(2):119–23.
Patterson MC. Gangliosidoses. Handb Clin Neurol. 2013;113:1707–8. https://doi.org/10.1016/B978-0-444-59565-2.00039-3.
Walterfanga M, Evansa A, Chee Leong Looid J, et al. The neuropsychiatry of neuroacanthocytosis syndrome. Neurosci Biobehav Rev. 2011;35:1275–83.
Tello C, Darling A, Lupo V, et al. On the complexity of clinical and molecular bases of neurodegeneration with brain iron accumulation. Clin Genet. 2017. https://doi.org/10.1111/cge.13057.
Saleem S, Aslam HM, Anwar M. Fahr’s syndrome: literature review of current evidence. Orphanet J Rare Dis. 2013;8:156.
Batla A, Tai XY, Schottlaender L, et al. Deconstructing Fahr’s disease/syndrome of brain calcification in the era of new genes. Parkinsonism Relat Disord. 2017;37:1–10.
Taly AB, Meenakshi-Sundaram S, Sinha S, Swamy HS, Arunodaya GR. Wilson disease: description of 282 patients evaluated over 3 decades. Medicine (Baltimore). 2007;86(2):112–21.
Bhatnagar N, Lingaiah P, Lodhi JS, Karkhur Y. Pathological fracture of femoral neck leading to a diagnosis of Wilson’s disease: a case report and review of literature. J Bone Metab. 2017 May;24(2):135–9. https://doi.org/10.11005/jbm.2017.24.2.135.
Aggarwal A, Bhatt M. Recovery from severe neurological Wilson’s disease with copper chelation. Int Rev Neurobiol. 2013;110:313–48.
Dardiotis E, Siokas V, Pantazi E, et al. A novel mutation in TREM2 gene causing Nasu-Hakola disease and review of the literature. Neurobiol Aging. 2017;53:194.e13–22.
Kaneko M, Sano K, Nakayama J, Amano N. Nasu-Hakola disease: the first case reported by Nasu and review: the 50th anniversary of Japanese society of neuropathology. Neuropathology. 2010;30(5):463–70.
Kang HE, Mo Y, Abd Rahim R, Lee HM, Ryou C. Prion diagnosis: application of real-time quaking-induced conversion. Biomed Res Int 2017;2017:5413936.
Valcour V, Paul R, Chiao S, Wendelken LA, Miller B. Screening for cognitive impairment in human immunodeficiency virus. Clin Infect Dis. 2011;53(8):836–42.
Read PJ, Donovan B. Clinical aspects of adult syphilis. Intern Med J. 2012;42(6):614–20.
Halperin JJ. Nervous system lyme disease: diagnosis and treatment. Curr Treat Options Neurol. 2013;15(4):454–64.
Halperin JJ. Lyme disease: a multisystem infection that affects the nervous system. Continuum (Minneap Minn). 2012;18(6 Infectious Disease):1338–50.
Puéchal X. Whipple’s disease. Ann Rheum Dis. 2013;72(6):797–803.
Graus F, Saiz A. Limbic encephalitis: an expanding concept. Neurology. 2008;70:500–1.
Serratrice G, Pellissier JF, Serratrice J, De Paula A. Limbic encephalitis – evolving concepts. Bull Acad Natl Med. 2008;192(8):1531–41.
Mocellin R, Walterfang M, Velakoulis D. Hashimoto’s encephalopathy: epidemiology, pathogenesis and management. CNS Drugs. 2007;21(10):799–811.
Victor M. Alcoholic dementia. Can J Neurol Sci. 1994;21:88–99.
Chalouhi C, Faesch S, Anthoine-Milhomme MC, et al. Neurological consequences of vitamin B12 deficiency and its treatment. Pediatr Emerg Care. 2008;24(8):538–41.
Ibrahim D, Froberg B, Wolf A, Rusyniak DE. Heavy metal poisoning: clinical presentations and pathophysiology. Clin Lab Med. 2006;26(1):67–97.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Ferrari, C., Nacmias, B., Sorbi, S. (2018). Rare Dementias. In: Galimberti, D., Scarpini, E. (eds) Neurodegenerative Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-72938-1_15
Download citation
DOI: https://doi.org/10.1007/978-3-319-72938-1_15
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-72937-4
Online ISBN: 978-3-319-72938-1
eBook Packages: MedicineMedicine (R0)